“Safety and Tolerability of Chikungunya Virus-Like Particle Vaccine in Healthy Adults: A Phase 1 Dose-Escalation Trial”, Lancet, vol. 384, pp. 2046-2052, 2014.
, “Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial”, J Infect Dis, vol. 211, pp. 549-557, 2015.
, “Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults”, PLoS One, vol. 10, p. e0123969, 2015.
, “Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate Vaccine Delivered by a Replication-Defective Recombinant Adenovirus Vector”, J Infect Dis, vol. 194, pp. 1638-1649, 2006.
, “Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults”, J Infec Dis, vol. 177, pp. 1230-46, 1998.
, “Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.”, J Infect Dis, vol. 177, no. 5, pp. 1230-46, 1998.
, “Chimpanzee Adenovirus Vector Ebola Vaccine - Preliminary Report”, N Engl J Med, 2014.
,